The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype
Timeframe: 0, 30, 60, 90, 120, 180 and 240 minutes post 5mg oral glipizide dose, Day 1 (visit 1)
Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to Genotype
Timeframe: 0,30,60,90,120,180 and 240 minutes on Day 1 (Visit 1)
Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2
Timeframe: Day 1 (Visit 1) and Day 8 (Visit 2)
Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2
Timeframe: Day 1 (Visit 1) and Day 8 (Visit 2)